Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
The money raised through the Offer for Sale goes to existing investors, not the company.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Concord Biotech Limited is an India based, research and development driven biopharmaceutical company incorporated in 1984 and headquartered in Ahmedabad, Gujarat. The company develops and manufactures fermentation based Active Pharmaceutical Ingredients, or APIs, along with select finished dosage formulations, with a particular focus on complex molecules used in immunosuppressant and oncology therapies. The company is counted among the leading global producers of a number of fermentation based APIs by volume, based on 2022 market data, and it sells across more than 70 countries including the United States, India, several European markets and Japan. Its manufacturing and research operations are concentrated in Gujarat, spanning both API and formulation facilities, supported by a portfolio of dozens of branded products across API and formulation categories. Concord Biotech operates in a specialised, technically demanding segment of the pharmaceutical industry where fermentation based synthesis requires significant process know how, and it has built its market position around this niche manufacturing capability rather than broad generic API production. The company's public issue in August 2023 was structured entirely as an offer for sale by an existing shareholder, so no fresh capital was raised by the company itself.
Concord Biotech raised approximately Rs 465 crore from anchor investors ahead of the public issue, with the anchor allocation priced at the upper end of the price band.
Source: RHP • Analysis provided for informational purposes
Last Updated: 18 July 2026, 5:30 AM
Leading position in fermentation based APIs
The company holds a significant share, by volume, of the global market for select fermentation based APIs used in immunosuppressant and oncology treatments, built on a wide portfolio of API and formulation products.
Favorable healthcare demand backdrop
India's domestic healthcare market is expected to grow at a high single to low double digit rate through the mid 2020s, aided by expanding private insurance coverage and rising healthcare spending.
Dependence on imported raw materials from China
Roughly half the company's material costs are sourced from China, so trade disruptions or import restrictions could affect production and margins.
Geographic concentration of operations
All manufacturing and R&D facilities are located in Gujarat, so a regional disruption could materially affect the business.
Customer concentration
A relatively small number of customers account for a large share of revenue, with the top five and top ten customers contributing roughly a third and nearly half of revenue respectively, so losing a major customer could hurt results.
MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.